Travere Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+12.03%
vs ±13.4% implied · ×0.90
shaded = implied · ▲▼ = realized
Travere Therapeutics, Inc.
50.38
Travere Therapeutics has 8 disclosed suppliers and 4 disclosed customers in SEC filings.
SentencePursuant to the Ligand License Agreement, we are obligated to pay to Ligand an escalating annual royalty between 15% and 17% of net sales of FILSPARI and any other products containing sparsentan or related compounds, which will impact our potential future profit from the commercialization of FILSPARI in the United States and sparsentan for the treatment of IgAN in the EU as well as sparsentan for the treatment of FSGS, if approved.
SentencePursuant to the Ligand License Agreement, we are obligated to pay Ligand (and Bristol-Myers Squibb Company ("BMS")) an escalating royalty between 15% and 17% of net sales of sparsentan, with payments due quarterly.
TVTX 10-Kaccession 0001438533-26-000014
SentenceCatalent Pharma Solutions manufactures FILSPARI and performs primary packaging.
TVTX 10-Kaccession 0001438533-25-000010
SentenceWe distribute our other products, Thiola and Thiola EC, through one direct to patient pharmacy, Eversana, who also provides our comprehensive patient support services in the United States.
TVTX 10-Kaccession 0001438533-25-000010
SentenceMission Pharmacal manufactures Thiola and Thiola EC.
TVTX 10-Kaccession 0001438533-25-000010
SentencePCI Pharma Services performs secondary packaging and serialization for FILSPARI.
TVTX 10-Kaccession 0001438533-25-000010
SentenceWe are party to a collaboration agreement with PharmaKrysto Limited and their early-stage cystinuria discovery program, whereby we are responsible for funding all research and development expenses for the pre-clinical activities associated with the cystinuria program.
TVTX 10-Kaccession 0001438533-25-000010
SentenceSTA Pharmaceutical Hong Kong Limited manufactures the active pharmaceutical ingredient for FILSPARI.
TVTX 10-Kaccession 0001438533-25-000010
SentenceIn the fourth quarter of 2025, our partner Renalys was acquired by and merged into Chugai, and as a result of the acquisition, Chugai gained exclusive rights to develop and commercialize sparsentan in Japan, South Korea, and Taiwan.
TVTX 10-Kaccession 0001438533-26-000014
SentenceWe are also party to license agreements with CSL Vifor and Renalys Pharma, Inc. pursuant to which we are entitled to receive certain payments contingent on the future achievement of specified milestones, and royalty payments based on potential future sales in specified licensed territories.
TVTX 10-Kaccession 0001438533-25-000010
SentenceWe are also party to license agreements with CSL Vifor and Renalys (which was acquired by Chugai in November 2025) pursuant to which we are entitled to receive certain payments contingent on the future achievement of specified milestones, and royalty payments based on potential future sales in specified licensed territories.
TVTX 10-Kaccession 0001438533-26-000014
SentenceWe are also party to license agreements with CSL Vifor and Renalys Pharma, Inc. pursuant to which we are entitled to receive certain payments contingent on the future achievement of specified milestones, and royalty payments based on potential future sales in specified licensed territories.
TVTX 10-Kaccession 0001438533-25-000010
Linked news
Expected move
Inputs8Q avg ±7.6%·×0.88·fair
straddle ±10.0%
spot 50.39exp Nov 20ATM strike 50ATM straddle 5.95IV 62%